Rommelag will showcase its blow-fill-seal technology that collectively offers container production, aseptic filling, and container closure.
Rommelag will be showcasing its blow-fill-seal (BFS) technology at Achema 2018. According to Rommelag, the technology offers three advantages-container production, aseptic filling, and container closure-in one operation under closed conditions.
The BFS aseptic filling systems is a safer, more cost-efficient solution for packaging liquid and semi-solid pharmaceutical products than a bottlepack aseptic system, the company said. The company has supplemented its bottlepack range with various inspection systems that ensure maximum safety and cost-effectiveness throughout the packaging process.
For quality assurance in pharmaceutical production, Rommelag will also highlight its solutions for different needs, including equipment requirements, automatic visual inspection, tightness checks, and fully automated monitoring of critical product features within in-process control.
On the pharma services side, Rommelag will discuss the tailored system configurations it offers, the in-house support it provides for the planning phase of pharmaceutical production, and the after-sales service it provides from installation of the system by its own technicians to maintenance, repair, and complex modifications and retrofits.
Achema 2018 runs from June 11–15 in Frankfurt, Germany.
Source: Rommelag, Hall 3.0, Booth D49
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.